Gastrointestinal Perforation as a Safety Concern Among Patients With Rheumatoid Arthritis Receiving JAK Inhibitor Therapy: A Systematic Review and Network Meta-Analysis.

ABSTRACT:

Objective

Gastrointestinal perforation (GIP) is a rare and life-threatening safety concern associated with JAK inhibitors (JAKi). We aimed to review the evidence regarding the risk of GIP associated with the use of JAKi in patients with rheumatoid arthritis (RA) using a systematic review and network meta-analysis approach.

Methods

A comprehensive literature search was conducted in PubMed, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov through August 2024. Included were randomized controlled trials (RCTs) comparing JAKi with other comparators in adult patients with RA (age ≥18 years) and reports of GIP. Risk ratios (RRs) with 95% confidence intervals (CIs) were estimated using a random-effects model. Surface under the cumulative ranking curves

SUBMITTER: Sathapanasiri T 

PROVIDER: S-EPMC12500504 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature